Sonoma Private Wealth LLC Sells 381 Shares of Pfizer Inc. (NYSE:PFE)

Sonoma Private Wealth LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 2.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,461 shares of the biopharmaceutical company’s stock after selling 381 shares during the quarter. Sonoma Private Wealth LLC’s holdings in Pfizer were worth $390,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Marshall Wace LLP lifted its holdings in shares of Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after acquiring an additional 8,378,173 shares during the period. Swedbank AB bought a new position in Pfizer during the first quarter worth about $172,902,000. Pzena Investment Management LLC boosted its holdings in Pfizer by 181.6% during the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Pfizer by 21.8% during the first quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after purchasing an additional 2,829,178 shares in the last quarter. Finally, 1832 Asset Management L.P. grew its stake in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after purchasing an additional 2,487,919 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.3 %

PFE stock traded down $0.10 during midday trading on Friday, reaching $29.17. The stock had a trading volume of 4,854,582 shares, compared to its average volume of 37,011,137. The firm has a market cap of $165.29 billion, a price-to-earnings ratio of -487.92, a PEG ratio of 1.30 and a beta of 0.67. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $29.05 and a two-hundred day simple moving average of $28.42.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the previous year, the firm posted $0.67 earnings per share. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.76%. Pfizer’s dividend payout ratio is presently -2,800.00%.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday. They set a “market perform” rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.